Laidlaw initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $25 price target Kazia is developing paxalisib, a novel dual PI3K/mTOR inhibitor, as a potential triple negative breast cancer treatment, the analyst tells investors in a research note. The firm says paxalisib already demonstrated “promising” early signs of clinical efficacy. It believes 2026 and 2027 could be a “catalyst-rich period” for Kazia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Licenses SETDB1 Epigenetic Platform to Bolster Oncology Pipeline
- Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer
- Kazia Therapeutics Announces Board Changes and AGM Outcomes as It Highlights Oncology Pipeline
- Kazia Therapeutics Taps Leerink for New ATM Facility as Cash Bolstered by Late-2025 PIPE
- Kazia Therapeutics Posts Wider Half-Year Loss but Bolsters Cash, Pipeline and Nasdaq Compliance